FP therapy for controlling malignant ascites in advanced pancreatic cancer patients

Hepato-Gastroenterology

Volumn 54, Issue 80, 2007, Pages 2383-2386

  Yonemori, Kan ^a   Okusaka, Takuji ^a   Ueno, Hideki ^a   Morizane, Chigusa ^a   Takesako, Yoriko ^a   Ikeda, Masafumi ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

5 Fluorouracil and cisplatin; Malignant ascites; Pancreatic cancer

Indexed keywords

CISPLATIN; FLUOROURACIL;

ADULT; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASCITES; CANCER GRADING; CANCER GROWTH; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOLOGY; DIARRHEA; FEMALE; HUMAN; HYPONATREMIA; LEUKOPENIA; MALE; NAUSEA; NEUTROPENIA; PANCREAS CANCER; PRIORITY JOURNAL; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; VOMITING; WORLD HEALTH ORGANIZATION;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASCITES; C-REACTIVE PROTEIN; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 37749046532     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD: Improvements in survival and clinical benefit with gemcitabine as first-line chemotherapy for patients with advanced pancreas cancer. J Clin Oncol 1997; 15:2403-2413.
2. Aslam N, Marino CR: Malignant ascites: Arch Intern Med 2001; 161:2733-2737.
3. Warshaw AL, Fernandez-del Catillo C: Pancreatic carcinoma. N Engl J Med 1992; 326:455-465.
4. Wils JA, Kok T, wagener DJTh, Selleslags J, Duez N: Activity of cisplatin in adenocarcinoma of the pancreas. Eur J Cancer 1993; 29A:203-204.
5. Kish JA, Weaver A, Jacobs J, Cummmings G, Al-Sarraf M: Cisplatin and 5-Fluorouracil infusion in patients with recurrent and disseminated epidermoid cancer of the head and neck. Cancer 1984; 53:1819-1824.
6. Rothman H, Cantrell Jr JE, Lpkitch J, Difino S, Harvey J, Ahlgren J, Freyer J: Continuous infusion 5-fluorouracil plus weekly cisplatin for pancreatic carcinoma: a Mid-Atlantic Oncology Program Study. Cancer 1991; 68:264-268.
7. Nose H, Okada S, Okusaka T, Furuse J, Yoshino M, Ogoshi K, Kato T, Miyaji M, Hoshino M, Ariyama J, Suyama M, Karasawa E, Yoshimori M: 5-Fluorouracil continuous infusion combined with cisplatin for advanced pancreatic cancer: a Japanese cooperative study. Hepatogastroenterology 1999; 46:3244-3248.
8. Okusaka T, Okada S, Ishi H, Nose H, Nakasuka H, Nakayama H, Nagahama H: Clinical response to systemic combined chemotherapy with 5-Fluorouracil and cisplatin (FP therapy) in patients with advanced pancreatic cancer: Jpn J Clin Oncol 1996; 26:215-220.
9. Ueno H, Okada S, Okusaka T, Ikeda M: Prognostic factors in patients with metastatic pancreatic adenocarcinoma receiving systemic chemotherapy. Oncology 2000; 59:296-301.
10. Fujishiro M, Okada S, Ueno H, Okusaka T, Bseda M, Watabnabe H, Tanaka N: Predictive factors for tumor response to chemotherapy in patients with pancreatic cancer. Hepatogastroenterology 2000; 47:1744-1746.
11. Los G, Mutsaers PH, van der Vygh WJ, Baldew GS, de Graaf PW, MacVie JG: Direct diffusion of cis-diamminedichloroplatinum (II) in intraperitoneal rat tumors after intraperitonal chemotherapy: a comparison with systemic chemotherapy. Cancer Res 1989; 49:3380-3384.
12. Tahara M, Ohtsu A, Boku N, Nagashima F, Muto M, Sano Y, Yoshida M, Mera K, Hironaka S, Tajiri H, Yoshida S: Sequential methotrexate and 5-fluorouracil therapy for gastric cancer patients with peritoneal dissemination: a retrospective study. Gastric Cancer 2001; 4:212-218.
13. Seino K, Sugoh T, Mikami Y, Hakamada K, Endoh M, Sasaki M, Konn M: A case of unresectable pancreatic cancer successfully treated with continuous venous daily infusion of 5-FU and low-dose CDDP. Gan To Kagaku Ryoho 1997; 24:1027-1030.
14. Chabner Bam Stoller RG, Hande K, Jabobs S, Young RC: Methotrexate disposition in humans: case studies in ovarian cancer and following high dose infusion. Drug Metab Rev 1978; 8:107-117.